Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multi-Center, Randomized, Open-Label Study to Evaluate Symptom Relief and Safety After Using Fexuprazan 40 Mg Compared to Esomeprazole 40 Mg in Patients With Gastroesophageal Reflux Disease (GERD)

NCT07326904 is registered in ClinicalTrials.gov with Indonesia University as lead sponsor.

NCT NCT07326904
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07326904 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multi-Center, Randomized, Open-Label Study to Evaluate Symptom Relief and Safety After Using Fexuprazan 40 Mg Compared to Esomeprazole 40 Mg in Patients With Gastroesophageal Reflux Disease (GERD)
Lead sponsor
Indonesia University
Phase
Phase 3
Overall status
Completed
Start date
August 28, 2024
Completion date
December 13, 2024
Enrollment
145 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

gastro oesophageal reflux disease